DE602004010529D1 - 2-amino-5-benzoylthiazol npy-antagonisten - Google Patents

2-amino-5-benzoylthiazol npy-antagonisten

Info

Publication number
DE602004010529D1
DE602004010529D1 DE602004010529T DE602004010529T DE602004010529D1 DE 602004010529 D1 DE602004010529 D1 DE 602004010529D1 DE 602004010529 T DE602004010529 T DE 602004010529T DE 602004010529 T DE602004010529 T DE 602004010529T DE 602004010529 D1 DE602004010529 D1 DE 602004010529D1
Authority
DE
Germany
Prior art keywords
benzoylthiazol
amino
sup
npy antagonists
antagonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
DE602004010529T
Other languages
English (en)
Other versions
DE602004010529T2 (de
Inventor
Werner Neidhart
Matthias Heinrich Nettekoven
Philippe Pflieger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE602004010529D1 publication Critical patent/DE602004010529D1/de
Application granted granted Critical
Publication of DE602004010529T2 publication Critical patent/DE602004010529T2/de
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE602004010529T 2003-08-12 2004-08-04 2-amino-5-benzoylthiazol npy-antagonisten Active DE602004010529T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03017634 2003-08-12
EP03017634 2003-08-12
PCT/EP2004/008698 WO2005014592A1 (en) 2003-08-12 2004-08-04 2-amino-5-benzoylthiazole npy antagonists

Publications (2)

Publication Number Publication Date
DE602004010529D1 true DE602004010529D1 (de) 2008-01-17
DE602004010529T2 DE602004010529T2 (de) 2008-11-27

Family

ID=34130066

Family Applications (1)

Application Number Title Priority Date Filing Date
DE602004010529T Active DE602004010529T2 (de) 2003-08-12 2004-08-04 2-amino-5-benzoylthiazol npy-antagonisten

Country Status (14)

Country Link
US (1) US7250431B2 (de)
EP (1) EP1658288B1 (de)
JP (1) JP2007501823A (de)
KR (1) KR20060037435A (de)
CN (1) CN100422179C (de)
AT (1) ATE380189T1 (de)
AU (1) AU2004263311A1 (de)
BR (1) BRPI0413500A (de)
CA (1) CA2533463A1 (de)
DE (1) DE602004010529T2 (de)
ES (1) ES2297437T3 (de)
MX (1) MXPA06001570A (de)
RU (1) RU2006107444A (de)
WO (1) WO2005014592A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE102005000858A1 (de) * 2005-01-05 2006-07-20 Merck Patent Gmbh Fluortenside
JP2009521461A (ja) * 2005-12-22 2009-06-04 アイカジェン， インコーポレイテッド カルシウムチャネルアンタゴニスト
CN102264228A (zh) 2008-10-22 2011-11-30 默沙东公司 用于抗糖尿病药的新的环状苯并咪唑衍生物
AU2009309037A1 (en) 2008-10-31 2010-05-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
ES2652662T3 (es) 2011-02-25 2018-02-05 Merck Sharp & Dohme Corp. Novedosos derivados de azabencimidazol cíclicos útiles como agentes antidiabéticos
AU2013296470B2 (en) 2012-08-02 2016-03-17 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2018106518A1 (en) 2016-12-06 2018-06-14 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1247547A (en) 1983-06-22 1988-12-28 Paul Hadvary Leucine derivatives
US4844839A (en) 1984-09-04 1989-07-04 Manchak Frank In situ treatment and analysis of wastes
US4776409A (en) 1984-09-04 1988-10-11 Manchak Frank Insitu waste impoundment treating apparatus and method of using same
US5246960A (en) 1984-12-21 1993-09-21 Hoffmann-La Roche Inc. Oxetanones
CA1328881C (en) 1984-12-21 1994-04-26 Pierre Barbier Process for the manufacture of oxetanones
CA1270837A (en) 1984-12-21 1990-06-26 Hoffmann-La Roche Limited Oxetanones
NL8620328A (nl) 1985-08-26 1987-08-03 Manchak Frank Inrichting voor het in situ behandelen van gevaarlijk afval en werkwijze voor het gebruiken daarvan.
CA2035972C (en) 1990-02-23 2006-07-11 Martin Karpf Process for the preparation of oxetanones
US5274143A (en) 1991-07-23 1993-12-28 Hoffmann-La Roche Inc. Process for the preparation of (R)-3-hexyl-5,6-dihydro-4-hydroxy-6-undecyl-2H-pyran-2-one and (R)-5,6-dihydro-6-undecyl-2H-pyran-2,4(3H)-dione
US6004996A (en) 1997-02-05 1999-12-21 Hoffman-La Roche Inc. Tetrahydrolipstatin containing compositions
US6267952B1 (en) 1998-01-09 2001-07-31 Geltex Pharmaceuticals, Inc. Lipase inhibiting polymers
DE19824175A1 (de) * 1998-05-29 1999-12-02 Novartis Ag Amino-azol-Verbindungen
EP1105123B1 (de) 1998-08-14 2004-04-07 F.Hoffmann-La Roche Ag Lipasehemmer und chitosan enthaltende pharmazeutische zusammensetzungen
CA2340056C (en) 1998-08-14 2007-01-09 F. Hoffmann-La Roche Ag Pharmaceutical compositions containing lipase inhibitors
AU2003210305B2 (en) * 2002-02-28 2006-07-06 F. Hoffmann-La Roche Ag Thiazole derivatives as NPY receptor antagonists
MXPA05001328A (es) * 2002-08-07 2005-04-28 Hoffmann La Roche Derivados de tiazol.

Also Published As

Publication number Publication date
BRPI0413500A (pt) 2006-10-10
MXPA06001570A (es) 2006-05-15
CN1852907A (zh) 2006-10-25
EP1658288B1 (de) 2007-12-05
DE602004010529T2 (de) 2008-11-27
US20050038089A1 (en) 2005-02-17
CA2533463A1 (en) 2005-02-17
KR20060037435A (ko) 2006-05-03
EP1658288A1 (de) 2006-05-24
US7250431B2 (en) 2007-07-31
JP2007501823A (ja) 2007-02-01
RU2006107444A (ru) 2007-09-20
CN100422179C (zh) 2008-10-01
WO2005014592A1 (en) 2005-02-17
AU2004263311A1 (en) 2005-02-17
ES2297437T3 (es) 2008-05-01
ATE380189T1 (de) 2007-12-15

Similar Documents

Publication Publication Date Title
TW200608972A (en) Aryl-pyridine derivatives
MX2010005824A (es) Derivados de aminotiazol.
TW200745032A (en) Novel heterobicyclic derivatives
MX2009003939A (es) Derivados de imidazolona e imidazolidinona como inhibidores de la 11-beta-hidroxiesteroide deshidrogenasa de tipo 1 para diabetes.
TW200626558A (en) Indazolone derivatives
NZ594597A (en) Substituted piperidines as ccr3 antagonists
TW200616958A (en) New alkyl-pyridines as 11-beta inhibitors for diabetes
ATE384058T1 (de) Thiazolderivate
WO2007130075A8 (en) Aminothiazole derivatives as human stearoyl-coa desaturase inhibitors
NO20093200L (no) Tiazolidinderivater
WO2006000371A3 (en) Pyrimidine derivatives as 11beta-hsd1 inhibitors
NO20084853L (no) Forbindelser som er agonister av muscarinreseptorer og som kan vaere effektive i behandling av smerte, Alzheimers sykdom og/eller schizofreni
TW200738241A (en) Pyridazine derivatives
DE602004008098D1 (de) Substituierte 2h-ä1,2,4ütriazoloä4,3-aüpyrazine als gsk-3-inhibitoren
NO20091409L (no) Pyridin-3-yl-derivater som immunmodulerende midler
TW200740764A (en) Pyrazolone derivatives
ATE390922T1 (de) 2-aminobenzothiazole als cb1 rezeptor inverse agonisten
MXPA04002338A (es) Derivados de carbazol y su uso como antagonistas receptores del npy5.
DE602006021539D1 (en) Morpholine als 5ht2c-agonisten
MX2009010567A (es) Derivados de imidazolidinona.
NO20085271L (no) Muscarin reseptoragonister som er effektive i behandling av smerte, Alzheimers sykdom og schizofreni
ATE380189T1 (de) 2-amino-5-benzoylthiazol npy-antagonisten
MX2010002584A (es) Derivados de piperidina como agonistas de receptores muscarinicos.
MX2010001020A (es) Derivados de pirimidina utiles para el tratamiento de condiciones inflamatorias o alergicas.
GB0314967D0 (en) Piperazine derivatives

Legal Events

Date Code Title Description
8364 No opposition during term of opposition